ALK and non-small cell lung carcinoma: The overall percentage of patients lost under treatment with ALK inhibitors in this “direct” way, i.e. 25-30% (Figure 2) x 67% (Figure 4A, dark blue sector) ≈ 20% defines the theoretical upper limit, i.e. approximately 80%, for implementation of any subsequent therapies in ALK+ NSCLC.